CT032 / CARsgen, Korea Kolmar - LARVOL DELTA

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=20 | Completed | Sponsor: CARsgen Therapeutics Co., Ltd. | Recruiting ➔ Completed | N=78 ➔ 20

CAR T-Cell Therapy • Enrollment change • Trial completion • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CXCL8 • IL10 • IL2 • IL6

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (clinicaltrials.gov) - P=N/A; N=18; Active, not recruiting; Sponsor: Kang YU; Recruiting ➔ Active, not recruiting; N=48 ➔ 18; Trial completion date: Dec 2021 ➔ Dec 2023; Trial primary completion date: Dec 2019 ➔ Dec 2020

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Esophageal Cancer • Follicular Lymphoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Hepatology • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Pancreatic Cancer • Solid Tumor • CD19

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (clinicaltrials.gov) - P=N/A; N=48; Recruiting; Sponsor: Kang YU; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Jun 2019 ➔ Dec 2019

Clinical • Enrollment open • Trial completion date • Trial primary completion date

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (clinicaltrials.gov) - P1/2; N=78; Recruiting; Sponsor: Carsgen Therapeutics, Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (clinicaltrials.gov) - P1/2; N=78; Not yet recruiting; Sponsor: Carsgen Therapeutics, Ltd.

Clinical • New P1/2 trial